Filing Details

Accession Number:
0001562180-24-008599
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-27 16:30:04
Reporting Period:
2024-12-24
Accepted Time:
2024-12-27 16:30:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1710072 Edgewise Therapeutics Inc. EWTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691494 Marc Semigran C/O Edgewise Therapeutics, Inc.
1715 38Th Street
Boulder CO 80301
Chief Development Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-24 29,709 $8.94 36,425 No 4 M Direct
Common Stock Disposition 2024-12-24 27,980 $29.66 8,445 No 4 S Direct
Common Stock Disposition 2024-12-24 1,729 $30.08 6,716 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-12-24 29,709 $0.00 29,709 $8.94
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
270,291 2032-12-30 No 4 M Direct
Footnotes
  1. Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
  3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. 1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.